{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:19:49Z","timestamp":1783095589016,"version":"3.54.6"},"reference-count":19,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epileptic Disorders"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Epilepsia partialis continua (EPC) is a form of focal motor status epilepticus (SE), which is commonly drug\u2010resistant requiring treatment with multiple antiseizure medications (ASM). There are no established guidelines for pharmacological management. Perampanel (PER), an AMPA receptor antagonist, has gained attention in treating SE based on limited case reports. This study evaluates the efficacy of PER in treating EPC.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We retrospectively analyzed the treatment response and adverse effects of PER in patients with EPC at our local centre between January 2024 and March 2025. Eight patients with EPC were included. The loading dose of PER ranged from 6\u2009mg to 20\u2009mg. A clinical response was defined as seizure freedom within 72\u2009h of initiating PER, with PER being the last ASM added.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n PER resulted in seizure termination in eight out of eight patients. Time to response ranged from less than 24\u2009h to 72\u2009h. Oral PER, up to a dose of 16\u2009mg, was well\u2010tolerated in conscious patients. Common side effects included sedation, delirium, agitation, and nausea.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Our real\u2010world data suggest that PER is an effective and well\u2010tolerated early adjunct therapy in EPC, particularly at higher oral loading doses in conscious patients.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/epd2.70318","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:35:56Z","timestamp":1783092956000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the efficacy and safety of perampanel in epilepsia partialis continua: A case series"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6717-4982","authenticated-orcid":false,"given":"Setareh","family":"Lahsaee","sequence":"first","affiliation":[{"name":"Department of Medicine (Neurology) Dalhousie University Halifax Nova Scotia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M.","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology) Dalhousie University Halifax Nova Scotia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Woodroffe","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology) Dalhousie University Halifax Nova Scotia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P.","family":"Whatley","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology) Dalhousie University Halifax Nova Scotia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"e_1_2_10_2_1","first-page":"47","article-title":"Eine besondere Form von corticaler Epilepsie","volume":"14","author":"Koshewnikow AJ","year":"1895","journal-title":"Neurol Centralbl"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2008.0161"},{"issue":"10","key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus: report of the ILAE task force","volume":"56","author":"Trinka E","year":"2015","journal-title":"Epilepsia"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1977.00500170020003"},{"issue":"2","key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/brain\/119.2.393","article-title":"Clinical and physiological features of epilepsia partialis continua","volume":"119","author":"Cockerell OC","year":"1996","journal-title":"Brain"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2016.10.010"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4944-04.2005"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108583"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-019-00704-9"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110655"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-024-02019-w"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14494"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2021.1262"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebcr.2017.09.004"},{"key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.yebeh.2018.07.004","article-title":"Perampanel in the treatment of status epilepticus: a systematic review","volume":"86","author":"Brigo F","year":"2018","journal-title":"Epilepsy Behav"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13061"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2025.01.005"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12804"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14082"}],"container-title":["Epileptic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epd2.70318","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/epd2.70318","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epd2.70318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:35:57Z","timestamp":1783092957000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/epd2.70318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":19,"alternative-id":["10.1002\/epd2.70318"],"URL":"https:\/\/doi.org\/10.1002\/epd2.70318","archive":["Portico"],"relation":{},"ISSN":["1294-9361","1950-6945"],"issn-type":[{"value":"1294-9361","type":"print"},{"value":"1950-6945","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"2026-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"epd2.70318"}}